remogliflozin etabonate

Remogliflozin etabonate is an orally administered small molecule prodrug of remogliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. After oral administration, it is converted to its active form, remogliflozin, which inhibits SGLT2 in the renal proximal tubules. This inhibition reduces glucose reabsorption in the kidneys and increases urinary glucose excretion, thereby lowering blood glucose levels. It is primarily indicated for the treatment of type 2 diabetes mellitus and has also been investigated for non-alcoholic steatohepatitis (NASH). The drug was originally developed by Kissei Pharmaceutical and GlaxoSmithKline and later further developed by Avolynt, BHV Pharma, Glenmark Pharmaceuticals, and Kissei Pharmaceutical[1][3][4][6].

Brand names

RemozenZucator

Other names

remogliflozin etabonate442201-24-34-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-beta-D-glucopyranoside